Protara Therapeutics, Inc. (TARA) Share-based Payment Arrangement, Expense USD 2013 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Protara Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2013 to 2024.
  • Protara Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $1.23 M, a 22.2% decline year-over-year.
  • Protara Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $5.74 M, a 10% decline year-over-year.
  • Protara Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $6.09 M, a 8.91% decline from 2022.
  • Protara Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $6.69 M.
  • Protara Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2019 was $943 K, a 72.5% decline from 2018.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $5.74 M $1.23 M -$349 K -22.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $6.09 M $1.45 M +$22 K +1.54% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-13
Q3 2023 $6.07 M $1.45 M +$10 K +0.7% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-03
Q2 2023 $6.06 M $1.62 M -$324 K -16.7% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-03
Q1 2023 $6.38 M $1.58 M -$304 K -16.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $6.69 M $1.43 M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-13
Q3 2022 $1.44 M -$1.28 M -47.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 $1.94 M -$1.06 M -35.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $1.88 M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q3 2021 $2.72 M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $3 M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q4 2019 $943 K -$34 K -$816 K -104% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-20
Q3 2019 $1.76 M $96 K -$808 K -89.4% Jul 1, 2019 Sep 30, 2019 10-Q 2019-10-31
Q2 2019 $2.57 M $101 K -$821 K -89% Apr 1, 2019 Jun 30, 2019 10-Q 2019-08-07
Q1 2019 $3.39 M $780 K -$41 K -4.99% Jan 1, 2019 Mar 31, 2019 10-Q 2019-05-08
Q4 2018 $3.43 M $782 K +$14 K +1.82% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-20
Q3 2018 $3.42 M $904 K +$157 K +21% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-31
Q2 2018 $3.26 M $922 K +$55 K +6.34% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $3.2 M $821 K -$24 K -2.84% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 $3.23 M $768 K -$76 K -9.01% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-13
Q3 2017 $3.3 M $747 K +$60 K +8.73% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $3.24 M $867 K -$79 K -8.35% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $3.32 M $845 K -$21 K -2.43% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $3.34 M $844 K +$174 K +26% Oct 1, 2016 Dec 31, 2016 10-K 2019-03-13
Q3 2016 $3.17 M $687 K +$76 K +12.4% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 $3.09 M $946 K +$470 K +98.7% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-07
Q1 2016 $2.62 M $866 K +$459 K +113% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q4 2015 $2.16 M $670 K +$445 K +198% Oct 1, 2015 Dec 31, 2015 10-K 2018-03-14
Q3 2015 $1.72 M $611 K +$426 K +230% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-07
Q2 2015 $1.29 M $476 K +$444 K +1388% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-08
Q1 2015 $849 K $407 K +$390 K +2294% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-09
Q4 2014 $459 K $225 K Oct 1, 2014 Dec 31, 2014 10-K 2017-03-16
Q3 2014 $185 K +$164 K +781% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-12
Q2 2014 $32 K Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-13
Q1 2014 $17 K Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-13
Q3 2013 $21 K Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.